Akmal Ahmed Safwat

MD, PhD, Klinisk lektor

Akmal Ahmed Safwat

Klinisk lektor

  • Institut for Klinisk Medicin - Kræftafdelingen
Postaddresse:
Palle Juul-Jensens Boulevard 35
8200
Aarhus N
Danmark

E-mail: akmal@oncology.au.dk

Mobil: +4529781229

Telefon: +4578464420

Fødselsår

1961

Uddannelser

2005Speciallæge Klinisk Onkologi, Danmark
1995Speciallæge stråleterapi, Egypten
1977-1983College of Medicine, Cairo University, Egypt

Akademiske grader

1995D.M.Sc. Onkologi
1988M.Sc. i strålingsterapi

Forskningsområder

Sarkom
Mesenchymal Cancer Stem Cell
Radiobiologi og immune effekter af helkrops bestråling

Nuværende ansættelse

2007-Overlæge og lektor ved Klinisk Onkologi, Onkologisk afdeling, Aarhus Universitetshospital, Danmark

Tidligere ansættelser

2005-2007Afdelingslæge, Onkologisk afdeling, Aarhus Universitetshospital, Danmark
2002Postdoc, Eksperimentel Klinisk Institut, Onkologisk afdeling, Aarhus Universitetshospital, Danmark

Publikationer og præsentationer

Publikationer: ?, Peer-reviewed artikler: 33, Bogkapitler: 2, H-index: 16, Citations: 77, Patenter: ?, Præsentationer ved videnskabelige møder (oral): 40.

Udvalgs- og bestyrelsesposter

Dansk Sarkom Gruppe

Organisering af kliniske forsøg

INITIATOR OG PRINCIPLE INVESTIGATOR:
Fase II forsøg af helkrops bestråling som adjuvant terapi for patienter med høj risiko NHL
Fase II forsøg af helkrops bestråling og IL-2 in metastatisk melignant melanom
Fase II forsøg af helkrops bestråling som adjuvant terapi af patienter over 60 år med høj risiko diffuse B-cell NHL

NATIONAL COORDINATOR:
EORTC Fase II forsøg om præoperativ stråleterapi for retroperitoneal sarkom

Vejledning

4 universitetsstuderende specialer, Aarhus Universitet (2007-2013)
4 ph.d. specialer (3 igangværende), Aarhus Universitetshospital (2002-2007)
3 ph.d. specialer, Cairo University (1996-2002)

Priser og udmærkelser

UICC "ICRETT" stipendiat ved:
Department of Medical Physics, Essen, Germany (Juli-August 1990)

The ESTRO-VARIAN Clinical/Radiobiology Research Award (1995)
UICC Yamagiwa-Yoshida Cancer Research Study Grant (1999)
A Danish Medical Research Council post-doctoral fellowship (January-December 2001)
William Nielsen honorary prise (2010)

Større forskningsbevillinger

The Danish Cancer Society (2001 & 2002)
The Danish Medical Research Council (2001)
King Christian the 10th Fund (2001)
A-P Møller and wife Fund (2001)
Preben and Anna Simonsen fund (2001)
The radiumstationen Research Fund (2001)
Direktør Leo Nielsen og hustrus Legat (2001)
Frits, Georg og Marie Cecilie Gluds Legat (2001)
Max og Inge Wørzners Mindelegat (2001)
The Danish Medical Research Council (2005)
Novo-Nordisk Fund (2005)
Agnes and Poul Friis Fund (2005)
Radiumstationen forskningsfond (2007)


Medlemsskaber

European Society for Therapeutic Radiology and Oncology (ESTRO)
Dansk Sarkom Gruppe (DSG)
Dansk Selskab for Klinisk Onkologi (DSKO)
Connective Tissue Oncology Society (CTOS)
International Pædiatric Radiation Oncology Society (PROS)

Publikationer

The Feasibility of Implementing Deep Inspiration Breath-Hold for Pediatric Radiation Therapy

Lundgaard, A. Y., Josipovic, M., Rechner, L. A., Bidstrup, P. E., Hansen, R., Damkjaer, S. S., Joergensen, M., Safwat, A., Specht, L., Hjalgrim, L. L. & Maraldo, M. V., apr. 2020, I: International Journal of Radiation Oncology Biology Physics. 106, 5, s. 977-984 8 s.

The association between socioeconomic position and tumour size, grade, stage, and mortality in Danish sarcoma patients - A national, observational study from 2000 to 2013

Raedkjaer, M., Maretty-Kongstad, K., Baad-Hansen, T., Safwat, A., Petersen, M. M., Keller, J. & Vedsted, P., feb. 2020, I: Acta Oncologica. 59, 2, s. 127-133 7 s.

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience

Aggerholm-Pedersen, N., Rossen, P., Rose, H. & Safwat, A., 2020, I: Translational Oncology. 13, 2, s. 295-299 5 s.

Use of Healthcare Services Two Years before Diagnosis in Danish Sarcoma Patients, 2000-2013

Rædkjær, M., Maretty-Kongstad, K., Baad-Hansen, T., Safwat, A., Petersen, M. M., Keller, J. & Vedsted, P., maj 2019, I: Sarcoma. 2019, 8108590.

The prognostic role of inflammation-scores on overall survival in lung cancer patients

Paulsen, B. S., Meldgaard, P., Sørensen, B. S., Safwat, A. A. & Aggerholm-Pedersen, N., mar. 2019, I: Acta Oncologica. 58, 3, s. 371-376 6 s.

Chondrosarcoma: the impact of comorbidity - 30 years of experience from a population-based database including 199 consecutive chondrosarcoma patients

Aggerholm-Pedersen, N., Maretty-Nielsen, K., Baerentzen, S., Jorgensen, P. H., Hansen, B. H., Baad-Hansen, T., Keller, J. & Safwat, A., 2019, I: Orthopedic research and reviews. 11, s. 109-116 8 s.

Serum Biomarkers as Prognostic Factors for Metastatic Sarcoma

Aggerholm-Pedersen, N., Maretty-Kongstad, K., Keller, J. Ø. & Safwat, A., 2019, I: Clinical Oncology. 31, 4, s. 242-249 8 s.

Soft Tissue Sarcomas of the Thoracic Wall: More Prone to Higher Mortality, and Local RecurrenceA Single Institution Long-Term Follow-up Study

Soerensen, T. R., Raedkjaer, M., Jorgensen, P. H., Hoejsgaard, A., Safwat, A. & Baad-Hansen, T., 2019, I: International Journal of Surgical Oncology. 2019, 7 s., 2350157.

Solitary Fibrous Tumour: A Single Institution Retrospective Study and Further Validation of a Prognostic Risk Assessment System

Friis, R. B., Safwat, A., Baad-Hansen, T. & Aggerholm-Pedersen, N., dec. 2018, I: Clinical Oncology. 30, 12, s. 798-804 7 s.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Guidelines Committee, PaedCan and ERN EURACAN, 1 okt. 2018, I: Annals of Oncology. 29, Supplement_4, s. 79-95 17 s.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

Robinson, M. H., Rutkowski, P., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., Blay, J. Y. & ESMO Guidelines Committee and EURACAN, 1 okt. 2018, I: Annals of Oncology. 29, Supplement_4, s. iv68-iv78 11 s.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

ESMO Guidelines Committee and EURACAN, 1 okt. 2018, I: Annals of Oncology. 29, Supplement_4, s. 268-269 2 s.

The impact of comorbidity on mortality in Danish sarcoma patients from 2000-2013: A nationwide population-based multicentre study

Raedkjaer, M., Maretty-Kongstad, K., Baad-Hansen, T., Jørgensen, P. H., Safwat, A., Vedsted, P., Petersen, M. M., Hovgaard, T., Nymark, T. & Keller, J., 1 jun. 2018, I: PLOS ONE. 13, 6, 13 s., e0198933.

TEDDI: radiotherapy delivery in deep inspiration for pediatric patients - a NOPHO feasibility study

Lundgaard, A. Y., Hjalgrim, L. L., Rechner, L. A., Josipovic, M., Joergensen, M., Aznar, M. C., Berthelsen, A. K., Borgwardt, L., Johansen, C., Loft, A., Safwat, A., Vaalavirta, L., Specht, L. & Maraldo, M. V., 27 mar. 2018, I: Radiation Oncology. 13, 1, 6 s., 56.

A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities

Maretty-Kongstad, K., Aggerholm-Pedersen, N., Keller, J. & Safwat, A., dec. 2017, I: Translational Oncology. 10, 6, s. 942-948 7 s.

Factors associated with reduced functional outcome and quality of life in patients having limb-sparing surgery for soft tissue sarcomas - a national multicenter study of 128 patients

Saebye, C., Fugloe, H. M., Nymark, T., Safwat, A., Petersen, M. M., Baad-Hansen, T., Krarup-Hansen, A. & Keller, J., feb. 2017, I: Acta Oncologica. 56, 2, s. 239-244 6 s.

Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma

Buvarp Dyrop, H., Vedsted, P., Rædkjær, M., Safwat, A. & Keller, J., 12 jan. 2017, I: Acta Orthopaedica. 88, 2, s. 211-216 6 s.

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Kollar, A., Jones, R. L., Stacchiotti, S., Gelderblom, H., Guida, M., Grignani, G., Steeghs, N., Safwat, A., Katz, D., Duffaud, F., Sleijfer, S., van der Graaf, W. T., Touati, N., Litiere, S., Marreaud, S., Gronchi, A. & Kasper, B., 2017, I: Acta Oncologica. 56, 1, s. 88-92 5 s.

A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma

Aggerholm-Pedersen, N., Sørensen, B. S., Overgaard, J., Toustrup, K., Bærentzen, S., Nielsen, O. S., Maretty-Kongstad, K., Nordsmark, M., Alsner, J. & Safwat, A., 25 okt. 2016, I: B J C. 115, 9, s. 1096-1104 9 s.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOSan open-label, international, randomised controlled trial-1): an open-label, international, randomised controlled trial

Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., Brichard, B., Brown, K. L. B., Butterfass-Bahloul, T., Calaminus, G., Daldrup-Link, H. E., Eriksson, M., Gebhardt, M. C., Gelderblom, H., Gerss, J., Goldsby, R., Goorin, A., Gorlick, R., Grier, H. E., Hale, J. P., Hall, K. S., Hardes, J., Hawkins, D. S., Helmke, K., Hogendoorn, P. C. W., Isakoff, M. S., Janeway, K. A., Jürgens, H., Kager, L., Kühne, T., Lau, C. C., Leavey, P. J., Lessnick, S. L., Mascarenhas, L., Meyers, P. A., Mottl, H., Nathrath, M., Papai, Z., Randall, R. L., Reichardt, P., Renard, M., Safwat, A. A., Schwartz, C. L., Stevens, M. C. G., Strauss, S. J., Teot, L., Werner, M., Sydes, M. R. & Whelan, J. S., okt. 2016, I: The Lancet Oncology. 17, 10, s. 1396-1408 13 s.

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma

Aggerholm-Pedersen, N., Maretty-Kongstad, K., Keller, J., Baerentzen, S. & Safwat, A., aug. 2016, I: Translational Oncology. 9, 4, s. 322-8 7 s.

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas

Vitfell-Rasmussen, J., Judson, I., Safwat, A., Jones, R. L., Rossen, P. B., Lind-Hansen, M., Knoblauch, P. & Krarup-Hansen, A., 14 jun. 2016, I: Sarcoma. 2016, 8 s., 2090271.

Primary breast sarcoma: A retrospective study over 35 years from a single institution

Holm, M. P., Aggerholm-Pedersen, N., Mele, M., Jørgensen, P. H., Baerentzen, S. & Safwat, A., maj 2016, I: Acta Oncologica. 55, 5, s. 584-90 7 s.

Characteristics of 64 sarcoma patients referred to a sarcoma center after unplanned excision

Dyrop, H. B., Safwat, A., Vedsted, P., Nielsen, K. M., Hansen, B. H., Jørgensen, P. H., Baad-Hansen, T. & Keller, J., feb. 2016, I: Journal of Surgical Oncology. 113, 2, s. 235-9 5 s.

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy

Aggerholm-Pedersen, N., Demuth, C., Safwat, A., Meldgaard, P., Kassem, M. & Sandahl Sorensen, B., 2016, I: Stem Cells and Development. 2016, s. 9601493

Routes to Diagnosis for Suspected Sarcoma: The Impact of Symptoms and Clinical Findings on the Diagnostic Process

Buvarp Dyrop, H., Vedsted, P., Rædkjær, M., Safwat, A. & Keller, J., 2016, I: Sarcoma. 2016, s. 8639272

Unsustained response to brentuximab as single agent therapy in a patient with CD30 positive angiosarcoma

Holm, M. P., Hjorthaug, K., Bærentzen, S. & Safwat, A. A., 2016, I: Acta Oncologica. 55, 2, s. 251-253 3 s.

The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia

Schack, L. M. H., Mouritsen, L. S., Mouritsen, L. S., Krarup-Hansen, A. & Safwat, A. A., jan. 2015, I: Acta Oncologica. 54, 1, s. 34-40 7 s.

Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature

Hygum, K., Wulff, C. N., Harsløf, T., Boysen, A. K., Rossen, P. B., Langdahl, B. L. & Safwat, A. A., 2015, I: B M C Cancer. 15, 5 s., 788.

Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center

Dyrop, H. B., Vedsted, P., Safwat, A., Maretty-Nielsen, K., Hansen, B. H., Jorgensen, P. H., Baad-Hansen, T. & Keller, J., dec. 2014, I: Acta Orthopaedica. 85, 6, s. 657-662 6 s.

The importance of reference gene analysis of formalin-fixed, paraffin-embedded samples from sarcoma patients - an often underestimated problem

Aggerholm-Pedersen, N., Safwat, A. A., Bærentzen, S., Nordsmark, M., Nielsen, O. S., Alsner, J. & Sørensen, B. S., dec. 2014, I: Translational Oncology. 7, 6, s. 687-93 7 s.

Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients

Safwat, A. A., Boysen, A., Lücke, A. & Rossen, P., okt. 2014, I: Acta Oncologica. 53, 10, s. 1451-4 4 s.

Prevalence and prognostic impact of comorbidity in soft tissue sarcoma: A population-based cohort study

Maretty-Nielsen, K., Aggerholm-Pedersen, N., Safwat, A., Baerentzen, S., Pedersen, A. B. & Keller, J., sep. 2014, I: Acta oncologica (Stockholm, Sweden). 53, 9, s. 1188-96 9 s.

The importance of standardized treatment in high-grade osteosarcoma: 30 years of experience from a hospital-based database

Aggerholm-Pedersen, N., Nielsen, K. M., Keller, J., Baerentzen, S., Schrøder, H., Jørgensen, P. H., Hansen, B. H., Nielsen, O. S. & Safwat, A., 24 jun. 2014, I: Acta Oncologica. s. 1-8 8 s.

Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients

Maretty-Nielsen, K., Aggerholm-Pedersen, N., Safwat, A. A., Jørgensen, P. H., Hansen, B. H., Baerentzen, S., Pedersen, A. B. & Keller, J., jun. 2014, I: Acta Orthopaedica. 85, 3, s. 323-32 10 s.

Validation of a Danish version of the Toronto Extremity Salvage Score questionnaire for patients with sarcoma in the extremities

Sæbye, C., Safwat, A. A., Kaa, A. K., Pedersen, N. A. & Keller, J., jan. 2014, I: Danish Medical Journal. 61, 1, 4 s., A4734.

Validation of a Danish version of the Toronto Extremity Salvage Score questionnaire for patients with sarcoma in the extremities

Saebye, C., Safwat, A., Kaa, A. K., Pedersen, N. A. & Keller, J., jan. 2014, I: Danish Medical Journal. 61, 1, 4 s., 4734.

Comorbidity in adult bone sarcoma patients: a population-based cohort study

Aggerholm-Pedersen, N., Maretty-Nielsen, K., Keller, J., Bærentzen, S. & Safwat, A., 2014, I: Sarcoma. 2014, 9 s., 690316.

Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study

Maretty-Nielsen, K., Aggerholm-Pedersen, N., Keller, J. Ø., Safwat, A. A., Baerentzen, S. & Pedersen, A. B., 2014, I: B M C Cancer. 14, 11 s., 682.

Cancer Patient Pathways shortens waiting times and accelerates the diagnostic process of suspected sarcoma patients in Denmark

Dyrop, H. B., Safwat, A., Vedsted, P., Maretty-Nielsen, K., Hansen, B. H., Jørgensen, P. H., Baad-Hansen, T., Bünger, C. & Keller, J., nov. 2013, I: Health Policy. 113, 1-2, s. 110-7 8 s.

Metastatic pattern, local relapse, and survival of patients with myxoid liposarcoma: a retrospective study of 45 patients

Fuglø, H. M., Nielsen, K. M., Hovgaard, D., Keller, J. Ø., Safwat, A. A. & Petersen, M. M., 20 jun. 2013, I: Sarcoma. 2013, 6 s., 548628.

Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark

Nielsen, K. M., Aggerholm-Pedersen, N., Keller, J., Safwat, A., Baerentzen, S. & Pedersen, A. B., 6 mar. 2013, I: Clinical epidemiology. 5, 1, s. 45-56 12 s.

Low-Grade Fibromyxoid Sarcoma: Incidence, Treatment Strategy of Metastases, and Clinical Significance of the FUS Gene

Nielsen, K. M., Baerentzen, S., Keller, J., Dyrop, H. B. & Safwat, A., 2013, I: Sarcoma. 2013, 6 s., 256280.

Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells

D'Andrea, F. P., Safwat, A. A., Burns, J. S., Kassem, M., Horsman, M. R. & Overgaard, J., jun. 2012, I: International Journal of Radiation Biology. 88, 6, s. 457-465 9 s.

Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy

Burns, J. S., Safwat, A., Grisendi, G., Kassem, M. & Dominici, M., 2012, I: Cancer Letters. 325, 1, s. 1-10 10 s.

Tumourigenicity and radiation resistance of mesenchymal stem cells

D'Andrea, F. P., Horsman, M. R., Kassem, M., Overgaard, J. & Safwat, A. A., 2012, I: Acta Oncologica. 51, 5, s. 669-679 11 s.

Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance

D'Andrea, F. P., Safwat, A. A., Kassem, M., Gautier, L., Overgaard, J. & Horsman, M. R., jun. 2011, I: Radiotherapy & Oncology. 99, 3, s. 373-378 6 s.

A Rare Case of CD30+, Radiation-Induced Cutaneous Angiosarcoma Misdiagnosed As T-Cell Lymphoma

Aggerholm-Pedersen, N., Bærentzen, S., Jørgensen, P. H. & Safwat, A., 7 feb. 2011, I: Journal of Clinical Oncology.

Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment

Farr, K. P. & Safwat, A. A., 2011, I: Case Reports in Oncology. 4, 1, s. 229-35 7 s.

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution

Aggerholm-Pedersen, N., Rasmussen, P., Dybdahl, H., Rossen, P., Nielsen, O. S. & Safwat, A., 2011, I: ISRN Oncology. 2011, s. 523915

Serum natrium determines outcome of treatment of advanced GIST with Imatinib: a retrospective study of 80 patients from a single institution

Pedersen, N., Rasmussen, P., Dybdahl, H., Rossen, P., Nielsen, O. S. & Safwat, A. A., 2011, I: ISRN Oncology. 1-7

Final results of a phase II Danish trial testing low dose total body irradiation following Six bi-weekly RCHOP-14 plus 2 estra Rituximab in elderly high-risk patients with aggressive CD20+ diffuse large B-cell lymphoma (DLBCL)

Safwat, A., Specht, L., Hansen, F., Hansen, M., Jurlander, J. & d'Amore, F. A., 2009, (Afsendt) I: Cancer.

Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation

Sørensen, F. B., Jensen, K., Vaeth, M., Hager, H., Funder, A. M. D., Safwat, A., Keller, J. & Christensen, M., 2008, I: Sarcoma. 2008, s. 874075

A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma

Safwat, A., Schmidt, H., Bastholt, L., Fode, K., Larsen, S., Aggerholm, N. & Maase, H. V. D., 2005, I: Radiother. Oncol.. 77, 2, s. 143-147

A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer

Ezzat, M., Shouman, T., Zaza, K., Safwat, A., El-Khoudary, A., El-Senosi, M. & Ezzat, I., 2005, I: J Egypt Natl Cancer Inst. 17, 2, s. 85-92

Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2

Safwat, A. A., Aggerholm-Pedersen, N., Roitt, I., Overgaard, J. & Hokland, M., jun. 2004, I: European Journal of Cancer. 40, 9, s. 1412-1417 6 s.

A phase II trial of adjuvant low-dose total body irradiation in non-Hodgkin's lymphoma patients following standard CHOP

Safwat, A., Bayoumi, Y., Akkoush, H. & Mahmoud, H. K., 2004, I: Acta Oncologica. 43, s. 480-485 6 s.

Low-dose total body irradiation augments the therapeutic effect of Interleukin-2 in a mouse model for metastatic malignant melanoma

Safwat, A. A., Aggerholm, N., Roitt, I., Overgaard, J. & Hokland, M., aug. 2003, I: Journal of Experimental Therapeutics and Oncology. 3, 4, s. 161-168 8 s.

The potential palliative role and possible immune modulatory effects of low-dose total body irradiation in relapsed or chemo-resistant non-Hodgkin's lymphoma

Safwat, A. A., Bayoumy, Y., El-Sharkawy, N., Shaaban, K., Mansour, O. & Kamel, A., 2003, I: Radiotherapy & Oncology. 69, 1, s. 33-36 4 s.

Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy

Safwat, A. A., Bentzen, S. M., Turesson, I. & Hendry, J. H., 1 jan. 2002, I: International Journal of Radiation Oncology, Biology, Physics. 52, 1, s. 198-204 7 s.

Time-course of the hazard of murine nephropathy induced by total-body irradiation

Safwat, A., Bentzen, S., Nielsen, O. S. & Overgaard, J., 2000, I: International Journal of Radiation Biology. 76, 7, s. 979-83 5 s.

A retrospective clinicopathological study of 37 patients with chordoma: A Danish national series.

Safwat, A., Nielsen, O. S., Jurik, A. G., Keller, J. Ø., Weeth, E., Lund, B. & Jensen, O. M., 1997, I: Sarcoma. 1, 3-4, s. 161-165 5 s.

Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide

Safwat, A., Bentzen, S. M., Nielsen, O. S., Mahmoud, H. K. & Overgaard, J., sep. 1996, I: Radiotherapy & Oncology. 40, 3, s. 249-257 9 s.

Effect of radiation dose rate and Cyclophosphamide on late pulmonary toxicity after total body radiation in a mouse model

Safwat, A., Nielsen, O. S., El-Badawy, S. & Overgaard, J., jan. 1996, I: International Journal of Radiation Oncology, Biology, Physics. 34, 1, s. 85-91 7 s.

Late renal damage after total body irradiation and bone marrow transplantation in a mouse model: effect of radiation fractionation

Safwat, A. A., Nielsen, O. S., el-Badawy, S. & Overgaard, J., jun. 1995, I: European Journal of Cancer. 31A, 6, s. 987-992 6 s.

Late renal damage after total body radiation and bone marrow transplantation in a mouse model: Effect of radiation fractionation

Safwat, A., Nielsen, O. S., El-Badawy, S. & Overgaard, J., jun. 1995, I: European Journal of Cancer. 31A, 6, s. 987-992 6 s.

Renal damage after total body irradiation in a mouse model for bone marrow transplantation: Effect of radiation dose rate

Safwat, A., Nielsen, O. S., El-Bakky, H. A. & Overgaard, J., mar. 1995, I: Radiotherapy & Oncology. 34, 3, s. 203-209 7 s.

The effect of sequence and time interval between cyclophosphamide and total body irradiation on lung and bone marrow damage following bone marrow transplantation in mice

Nielsen, O. S., Safwat, A. & Overgaard, J., okt. 1993, I: Radiotherapy & Oncology. 29, 1, s. 51-59 9 s.

Influence of time between total body irradiation and cyclophosphamide in bone marrow transplantation. A study on mice.

Nielsen, O. S., Safwat, A. & Overgaard, J., 1993, I: Radiology and Oncology. 29, s. 51-59

Is kidney the real dose limiting organ after total body irradiation and bone marrow transplatation?

Safwat, A., Nielsen, O. S. & Overgaard, J., 1993, I: European Journal of Cancer. 29A, 6, s. 921

Is kidney the real dose-limiting organ after total body irradiation and bone marrow transplantation?

Safwat, A. A., Nielsen, O. S. & Overgaard, J., 1993, I: European journal of cancer (Oxford, England : 1990). 29A, 6, s. 929 1 s.